← Leaderboards
Alexander Drilon
Sloan-Kettering Inst Can Research
$4,847,187
Attributed
$9,328,186
Total exposure
4
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.9M · FY2018–25$2M$1.5M$1M$500K$0
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$9,328,186 · 4
By mechanism
R01$7,348,477 · 3
T32$1,979,709 · 1
Top collaborators
- Michael F. Berger4 shared
- Michelle Ginsberg4 shared
- Gopa Iyer4 shared
- Omar Abdel-Wahab2 shared
- Dean F. Bajorin2 shared
- Maurizio Scaltriti2 shared
- Andrea Ventura2 shared
Most similar at Sloan-Kettering Inst Can Research
Same institution · by research overlap
- David B. Solit$21,393,031
- Elisa De Stanchina$4,011,743
- Sarat Chandarlapaty$10,852,142
- Andrea Ventura$13,315,692
- Gabriela Chiosis$23,584,161
Others in their field
Other Emerging Leaders on “Malignant Neoplasms”
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
- Leonard Freedmand · Leidos Biomedical Research, Inc.$108,968,336
- Beverly Hayes · Leidos Biomedical Research, Inc.$98,336,166
- Martha Hering · Westat, Inc.$57,098,843
Research focus
Malignant NeoplasmsTumorPlasmaPharmaceutical PreparationsSamplingResponseMutationDeep SequencingPreventProgression-Free SurvivalsPathway InteractionsCell Free DnaMolecularBiopsyProspectiveCo-Clinical TrialGenomicsIn VitroLeadershipIn VivoExome SequencingCombined Modality TherapyAdultCollection
Grant awards (17)
Integration of Imaging and Circulating Plasma Cell-Free DNA Sequencing Using MSK-ACCESS to Monitor Treatment Response and Predict Progression in Patients With Multiple Cancers on Targeted Therapy$734,511
R01 · FY2025 · CA
Predicting sensitivity and resistance in RET-driven cancers$404,888
R01 · FY2025 · CA · contact PI
Investigational Cancer Therapeutics Training Program (ICTTP)$59,553
T32 · FY2025 · CA · contact PI
Integration of Imaging and Circulating Plasma Cell-Free DNA Sequencing Using MSK-ACCESS to Monitor Treatment Response and Predict Progression in Patients With Multiple Cancers on Targeted Therapy$697,771
R01 · FY2024 · CA
Investigational Cancer Therapeutics Training Program (ICTTP)$584,360
T32 · FY2024 · CA · contact PI
Predicting sensitivity and resistance in RET-driven cancers$384,644
R01 · FY2024 · CA · contact PI
Investigational Cancer Therapeutics Training Program$759,367
T32 · FY2023 · CA · contact PI
Integration of Imaging and Circulating Plasma Cell-Free DNA Sequencing Using MSK-ACCESS to Monitor Treatment Response and Predict Progression in Patients With Multiple Cancers on Targeted Therapy$719,326
R01 · FY2023 · CA
Predicting sensitivity and resistance in RET-driven cancers$396,790
R01 · FY2023 · CA · contact PI
Integration of Imaging and Circulating Plasma Cell-Free DNA Sequencing Using MSK-ACCESS to Monitor Treatment Response and Predict Progression in Patients With Multiple Cancers on Targeted Therapy$734,122
R01 · FY2022 · CA
Investigational Cancer Therapeutics Training Program$576,429
T32 · FY2022 · CA · contact PI
Predicting sensitivity and resistance in RET-driven cancers$396,790
R01 · FY2022 · CA · contact PI
Understanding tumor addiction to TRK fusions and sensitivity to TRK inhibition$628,810
R01 · FY2021 · CA · contact PI
Predicting sensitivity and resistance in RET-driven cancers$404,888
R01 · FY2021 · CA · contact PI
Understanding tumor addiction to TRK fusions and sensitivity to TRK inhibition$628,810
R01 · FY2020 · CA · contact PI
Understanding tumor addiction to TRK fusions and sensitivity to TRK inhibition$609,943
R01 · FY2019 · CA
Understanding tumor addiction to TRK fusions and sensitivity to TRK inhibition$607,184
R01 · FY2018 · CA